Akebia Therapeutics (AKBA)

Akebia Therapeutics (AKBA) Stock Price & Analysis


AKBA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.24 - $1.84
Previous Close$1.14
Average Volume (3M)1.74M
Market Cap
Enterprise Value$215.07M
Total Cash (Recent Filing)$53.57M
Total Debt (Recent Filing)$53.97M
Price to Earnings (P/E)-2.1
Nov 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding188,313,807
10 Day Avg. Volume1,051,196
30 Day Avg. Volume1,740,938
Standard Deviation0.31
Financial Highlights & Ratios
Price to Book (P/B)-1.53
Price to Sales (P/S)5.13
Price to Cash Flow (P/CF)14.70
P/FCF Ratio14.70
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.15
Enterprise Value/Gross Profit0.74
Enterprise Value/Ebitda-87.64
Price Target Upside269.52% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $0.24 and its highest was $1.84 in the past 12 months.
    What is Akebia Therapeutics’s market cap?
    Currently, no data Available
    When is Akebia Therapeutics’s upcoming earnings report date?
    Akebia Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is in 37 days.
      How were Akebia Therapeutics’s earnings last quarter?
      Akebia Therapeutics released its earnings results on Aug 25, 2023. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.025 by -$0.035.
        Is Akebia Therapeutics overvalued?
        According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Akebia Therapeutics pay dividends?
          Akebia Therapeutics does not currently pay dividends.
          What is Akebia Therapeutics’s EPS estimate?
          Akebia Therapeutics’s EPS estimate is -$0.09.
            How many shares outstanding does Akebia Therapeutics have?
            Akebia Therapeutics has 188,313,810 shares outstanding.
              What happened to Akebia Therapeutics’s price movement after its last earnings report?
              Akebia Therapeutics reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.025. Following the earnings report the stock price went down -8%.
                Which hedge fund is a major shareholder of Akebia Therapeutics?
                Among the largest hedge funds holding Akebia Therapeutics’s share is Graham Capital Management, L.P.. It holds Akebia Therapeutics’s shares valued at 24K.


                  Akebia Therapeutics Stock Smart Score

                  The Akebia Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Akebia Therapeutics

                  Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The firm also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. The company was founded by Joseph H. Gardner, John M. Rice, Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.


                  Top 5 ETFs holding AKBA

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold AKBA. The ETFs are listed according to market value of AKBA within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  TRACON Pharmaceuticals
                  Mersana Therapeutics
                  Bellicum Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis